TRSB.F Stock Overview

An investment holding company, develops, produces markets, and sells biopharmaceutical products in Mainland China and internationally. More details

TRSB.F fundamental analysis
Snowflake Score
Valuation	4/6
Future Growth	3/6
Past Performance	2/6
Financial Health	6/6
Dividends	3/6

Rewards

Trading at 68.9% below our estimate of its fair value

Earnings are forecast to grow 16.41% per year

Risk Analysis

Shares are highly illiquid

Unstable dividend track record

My Notes

Capture your thoughts, links and company narrative

3SBio Inc. Competitors

MiMedx Group

NasdaqCM:MDXG

US$1.3b

ACADIA Pharmaceuticals

NasdaqGS:ACAD

US$2.8b

Dynavax Technologies

NasdaqGS:DVAX

US$1.7b

MannKind

NasdaqGM:MNKD

US$1.9b

Price History & Performance

Summary of share price highs, lows and changes for 3SBio
Historical stock prices
Current Share Price	HK$0.83
52 Week High	HK$0.83
52 Week Low	HK$0.72
Beta	0.73
1 Month Change	n/a
3 Month Change	n/a
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	-42.10%
Change since IPO	-65.79%

Recent updates

Shareholder Returns

	TRSB.F	US Biotechs	US Market
7D	n/a	-3.6%	-2.4%
1Y	n/a	-2.6%	23.4%

Return vs Industry: Insufficient data to determine how TRSB.F performed against the US Biotechs industry.

Return vs Market: Insufficient data to determine how TRSB.F performed against the US Market.

Price Volatility

Is TRSB.F's price volatile compared to industry and market?
TRSB.F volatility
TRSB.F Average Weekly Movement	n/a
Biotechs Industry Average Movement	10.8%
Market Average Movement	6.3%
10% most volatile stocks in US Market	16.8%
10% least volatile stocks in US Market	3.1%

Stable Share Price: TRSB.F's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: Insufficient data to determine TRSB.F's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
1993	5,607	Jing Lou	www.3sbio.com

3SBio Inc., an investment holding company, develops, produces markets, and sells biopharmaceutical products in Mainland China and internationally. The company provides TPIAO, a recombinant human thrombopoietin to treat chemotherapy-induced thrombopenia and immune thrombocytopenia; Cipterbin, an anti-HER2 monoclonal antibody for the treatment of HER2-positive metastatic breast cancer; TNF, pre-filled aqueous injection solution. It also offers YISAIPU, the receptor fusion tumor necrosis factor inhibitor; Mandi-minoxidil tincture, an OTC external medicine for treating hair loss; EPIAO and SEPO, an erythropoietin injection; SPARIN, an injectable low-molecular-weight heparin calcium.

3SBio Inc. Fundamentals Summary

How do 3SBio's earnings and revenue compare to its market cap?
TRSB.F fundamental statistics
Market cap	US$1.83b
Earnings (TTM)	US$227.33m
Revenue (TTM)	US$1.15b

8.1x

P/E Ratio

1.6x

P/S Ratio

Is TRSB.F overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
TRSB.F income statement (TTM)
Revenue	CN¥8.42b
Cost of Revenue	CN¥1.18b
Gross Profit	CN¥7.24b
Other Expenses	CN¥5.58b
Earnings	CN¥1.66b

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	0.70
Gross Margin	85.94%
Net Profit Margin	19.69%
Debt/Equity Ratio	24.7%

How did TRSB.F perform over the long term?

See historical performance and comparison

Dividends

4.0%

Current Dividend Yield

33%

Payout Ratio

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2024/12/21 04:21
End of Day Share Price	2024/12/18 00:00
Earnings	2024/06/30
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

3SBio Inc. is covered by 34 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Sharon Shi	BOCI Research Ltd.
Ruyi Tang	BOCI Research Ltd.
Difei Yang	Capstone Investments